Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protein serine threonine kinase inhibitor therapeutic - Boehringer Ingelheim

X
Drug Profile

Protein serine threonine kinase inhibitor therapeutic - Boehringer Ingelheim

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Immunological disorders

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Immunological-disorders in Germany
  • 28 Jan 2021 Protein serine threonine kinase inhibitor therapeutic - Boehringer Ingelheim is available for licensing as of 28 Jan 2021. https://www.boehringer-ingelheim.com/partnering (Boehringer Ingelheim Website, January 2021)
  • 30 Sep 2020 Phase-I clinical trials in Immunological disorders in Germany (unspecified route) (Boehringer Ingelheim pipeline, September 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top